Poor Chinese Sales Of Foreign-Funded Drugs

15 October 1997

Only 13% of all pharmaceuticals produced by foreign-fundedpharmaceutical companies in China are being sold on the Chinese market, reports the China Daily Business Weekly. These companies are said to find export markets more profitable than China.

It is also reported that over 10 Chinese and foreign drugs producers, including Roche, Kirin and Shanghai Xianfeng Pharmaceutical, have invested in the National Biotechnology and Pharmaceutical Industries Development Center in Zhangjiang. The Center has been dubbed China's "pharmaceutical valley."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight